Screener
BioMarin Pharmaceuticals BMRN Business Segments — Other segment expense, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and early pipeline | 85,069 | 95,968 | 172,360 | 186,438 |
| Later-stage clinical programs | 50,295 | 13,133 | 86,472 | 27,424 |
| Marketed products | 71,588 | 52,207 | 126,916 | 106,177 |
| SG&A expenses | ||||
| S&M expenses | 142,186 | 122,100 | 267,113 | 224,631 |
| G&A expenses | 253,363 | 110,179 | 386,726 | 213,764 |
| Other segment expense, net (1) | 139,650 | 41,201 | 168,246 | 84,255 |
| Net income | $44,762 | $240,532 | $150,289 | $426,218 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's business segments — other segment expense, net?
- BioMarin Pharmaceuticals (BMRN) reported business segments — other segment expense, net of $139.65M in Q2 2026.
- How has BioMarin Pharmaceuticals's business segments — other segment expense, net changed year-over-year?
- BioMarin Pharmaceuticals's business segments — other segment expense, net increased by 238.9% year-over-year, from $41.2M to $139.65M.
- What is the long-term trend for BioMarin Pharmaceuticals's business segments — other segment expense, net?
- Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's business segments — other segment expense, net has grown at a 55.2% compound annual growth rate (CAGR), from -$21.39M to $79.96M.
- What does business segments — other segment expense, net mean?
- This captures miscellaneous income or expenses specific to the reportable segment that are not categorized as cost of sales, marketing, or general administration. It may include items such as collaboration payments, royalties, or non-recurring operational adjustments. It provides a view into the non-core financial activities impacting the segment's bottom line.
Ask your AI about BioMarin Pharmaceuticals's business segments — other segment expense, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude